丹参酮ⅡA对化疗治疗非小细胞肺癌的疗效及P-gp表达的影响  

Research of Tanshinone ⅡA Efficacy of Chemotherapy on Non-small Cell Lung Cancer and P-gp Expression

作　　者：郭忠聪[1] 谢琼[1] 

机构地区：[1]湖南中医药大学第一附属医院,湖南长沙410003

出　　处：《中国中医急症》2013年第5期722-724,共3页Journal of Emergency in Traditional Chinese Medicine

基　　金：湖南省中医药管理局科研基金项目(2008100)

摘　　要：目的观察丹参酮ⅡA对TP方案治疗非小细胞肺癌(NSCLC)的临床疗效的影响。方法将患者随机分为两组,治疗组给予TP方案化疗配合丹参酮ⅡA;对照组只使用TP方案化疗。观察2个周期。结果治疗组实体瘤有效率为56.25%,高于对照组的37.50%。且治疗前后P-gp变化,治疗组和对照组之间差异有统计学意义。结论丹参酮ⅡA可以提高TP方案治疗NSCLC的疗效,丹参酮ⅡA不能显著改善NSCLC化疗后的生活质量,也不会增加TP治疗NSCLC的毒副反应,是临床上可以选择的肺癌化疗增效、安全的药物之一。Objective： To observe the effect of tanshinone Ⅱ A in Clinical efficacy in the treatment of non-small cell lung cancer by TP. Methods： The patients were randomly divided into two groups. The treatment group were give given TP regimen with tanshinone Ⅱ A. The control group were only give given the TP chemotherapy. Two cycles treatment were observed. Results： effective rate of Solid tumors of the treatment group was 56.25% which, higher than those in the control group which was 37.50%. The chang of P-gp before and after treatment,There were significant differences between the treatment group and the control group. Conclusion： Tanshinone Ⅱ A can improve the efficacy of the TP in NSCLC,which can not significantly improve the quality of life in NSCLC after chemotherapy and increase the toxicity of the TP in NSCLC. It is one of the safety and efficiency drug which can be choosed to treatment lung cancer in cliniealion.

关 键 词：非小细胞肺癌 丹参酮ⅡA 临床研究 毒副反应 P—gp 

分 类 号：R730.59[医药卫生—肿瘤]